|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 LAWS OF MARYLAND
|
|
|
|
|
Ch. 281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(b) The purpose of the Program is to provide Medicare PART D beneficiaries,
who [lack prescription drug coverage, with access to affordable, medically necessary
prescription drugs until such time as an outpatient prescription drug benefit is
provided through the federal Medicare program] MEET PROGRAM ELIGIBILITY
REQUIREMENTS, WITH A STATE SUBSIDY FOR A PORTION OF THEIR:
(1) MEDICARE PART D PRESCRIPTION DRUG PLAN PREMIUM AND
DEDUCTIBLE; OR
(2) MEDICARE ADVANTAGE PLAN PREMIUM AND DEDUCTIBLE RELATED
TO A PRESCRIPTION DRUG BENEFIT.
(c) [The Program shall be administered by a carrier as provided under §
14-106(d) of this title] THE BOARD SHALL CONTRACT WITH A THIRD PARTY TO
ADMINISTER THE PROGRAM.
(d) The [carrier that administers] ADMINISTRATOR OF the Program shall:
(1) submit a detailed financial accounting of the Program to the Board as
often as the Board requires;
(2) collect and submit to the Board data regarding the utilization
patterns and costs for Program enrollees; and
(3) develop and implement a marketing plan targeted at eligible
individuals throughout the State.
14-512.
(a) The Program shall:
(1) subject to the moneys available in the segregated account under §
14-504 of this subtitle, provide benefits to the maximum number of individuals
eligible for enrollment in the Program; AND
[(2) require a monthly premium charge of $10 per enrollee;
(3) not require a deductible; and
(4) limit the copay charged an enrollee to:
(i) $10 for a prescription for a generic drug;
(ii) $20 for a prescription for a preferred brand name drug; and
(iii) $35 for a prescription for a nonpreferred brand name drug.]
(2) PROVIDE A STATE SUBSIDY FOR A PORTION OF THE COST OF
MEDICARE PART D AND MEDICARE ADVANTAGE PLAN DRUG-RELATED PREMIUMS
AND DEDUCTIBLES.
(b) [The Board may limit the total annual benefit to $1,000 per individual]
THE SUBSIDY REQUIRED UNDER SUBSECTION (A) OF THIS SECTION SHALL BE EQUAL
TO:
- 1456 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
